One point in Adbry's favour is that some patients will be able to administer the injectable drug just once per month. after a lead-in period of dosing every other week. Dupixent's label currently ...

With the approval of Dupixent and Adbry, however, clinicians are less likely to prescribe biologics that have not been specifically FDA approved for the treatment of atopic dermatitis. Dupixent ...